PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Gynecologic Oncology

Volumn 139, Issue 1, 2015, Pages 59-62

  Smith, Haller J ^a   Walters Haygood, Christen L ^b   Arend, Rebecca C ^b   Leath, Charles A ^b   Straughn, J Michael ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

BRCA; Cost effectiveness; Olaparib; Ovarian cancer; PARP inhibitiors

Indexed keywords

CARBOPLATIN; OLAPARIB; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

CANCER RECURRENCE; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GERMLINE MUTATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PLATINUM SENSITIVE RECURRENT OVARIAN CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; UNITED STATES; WILD TYPE; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; ECONOMICS; GENETICS; MAINTENANCE CHEMOTHERAPY; OVARIAN NEOPLASMS; PROCEDURES; STATISTICAL MODEL; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MAINTENANCE CHEMOTHERAPY; MODELS, ECONOMIC; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; UNITED STATES;

EID: 84943366215     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.08.013     Document Type: Conference Paper

References (21)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 1 2014 9 29
2. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look, and et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1 1996 1 6
3. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, and et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 21 17 2003 3194 3200
4. M. Markman, P.Y. Liu, S. Wilczynski, B. Monk, L.J. Copeland, R.D. Alvarez, and et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 21 13 2003 2460 2465
5. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen, and et al. A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 26 2011 2484 2496
6. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, and et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N. Engl. J. Med. 366 15 2012 1382 1392
7. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, and et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 7035 2005 917 921
8. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, and et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 361 2 2009 123 134
9. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, and et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol. 15 8 2014 852 861
10. M.K. Parmar, J.A. Ledermann, N. Colombo, A. du Bois, J.F. Delaloye, G.B. Kristensen, and et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 9375 2003 2099 2106
11. K. Alsop, S. Fereday, C. Meldrum, A. deFazio, C. Emmanuel, J. George, and et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30 21 2012 2654 2663
12. B. Kaufman, R. Shapira-Frommer, R.K. Schmutzler, M.W. Audeh, M. Friedlander, J. Balmana, and et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33 3 2015 244 250
13. A.A. Secord, J.C. Barnett, J.A. Ledermann, B.L. Peterson, E.R. Myers, and L.J. Havrilesky Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer Int. J. Gynecol. Cancer 23 5 2013 846 852
14. National Comprehensive Cancer Network Genetic/familial high-risk assessment: breast and ovarian 2014 Available from: www.nccn.org 12/17/2014
15. Society of Gynecologic Oncology SGO clinical practice statement: genetic testing for ovarian cancer 2014 Available from: www.sgo.org/clinical-practice/guidelines/genetic-testing-for-ovarian-cancer/ 12/17/2014
16. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 7353 2011 609 615
17. D.E. Cohn, K.H. Kim, K.E. Resnick, D.M. O'Malley, and J.M. Straughn Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29 10 2011 1247 1251
18. A.B. Mariotto, K.R. Yabroff, Y. Shao, E.J. Feuer, and M.L. Brown Projections of the cost of cancer care in the United States: 2010-2020 J. Natl. Cancer Inst. 103 2 2011 117 128
19. T. Fojo, and C. Grady How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question J. Natl. Cancer Inst. 101 15 2009 1044 1048
20. A. du Bois, A. Floquet, J.W. Kim, J. Rau, J.M. Del Campo, M. Friedlander, and et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 32 30 2014 3374 3382
21. M. Markman, P.Y. Liu, J. Moon, B.J. Monk, L. Copeland, S. Wilczynski, and et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial Gynecol. Oncol. 114 2 2009 195 198